Amgen (NASDAQ:AMGN – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 22.300-23.500 for the period, compared to the consensus EPS estimate of 22.390. The company issued revenue guidance of $38.2 billion-$39.4 billion, compared to the consensus revenue estimate of $37.8 billion.
Amgen Stock Performance
Shares of NASDAQ AMGN traded up $11.76 during midday trading on Tuesday, hitting $390.63. 3,572,609 shares of the company’s stock were exchanged, compared to its average volume of 2,737,477. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $210.83 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 3.90 and a beta of 0.41. Amgen has a 12 month low of $269.77 and a 12 month high of $398.00. The company’s 50 day moving average price is $357.39 and its 200 day moving average price is $354.35.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts predict that Amgen will post 22.31 earnings per share for the current fiscal year.
Amgen Announces Dividend
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on AMGN. BMO Capital Markets restated an “outperform” rating and set a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. The Goldman Sachs Group set a $389.00 price objective on Amgen in a report on Friday, June 5th. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $357.00.
Read Our Latest Analysis on AMGN
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of $10.1 billion, up 10% year over year. Adjusted EPS was $6.29, above the $5.62 consensus estimate, while GAAP EPS increased 65% to $4.37. Operating income rose to $3.5 billion, and the company generated $3.5 billion in free cash flow. Amgen second-quarter sales rise 9%, profit tops Street view
- Positive Sentiment: Growth products performed well: Repatha sales climbed 37% to $953 million and EVENITY sales rose 38% to $714 million. Overall product sales increased 9%, with 22 products delivering double-digit growth, helping offset declines in older medicines. Amgen Q2 revenue rises 10% to $10.1 billion
- Positive Sentiment: 2026 outlook was raised: Amgen forecast revenue of $38.2 billion to $39.4 billion, above the roughly $37.8 billion analyst consensus. EPS guidance was set at $22.30 to $23.50, broadly in line with expectations, signaling confidence in sales growth. Amgen lifts outlook on strong drug sales
- Neutral Sentiment: Obesity pipeline update was mixed: Amgen halted development of a Phase 1 obesity treatment, reducing near-term pipeline optionality, but continues advancing MariTide, including an extension of its obesity study. Amgen obesity pipeline update
- Negative Sentiment: Legacy-product sales declined sharply: Prolia revenue fell 32% to $759 million and XGEVA sales dropped 34% to $352 million, highlighting continued pressure on parts of Amgen’s established portfolio.
- Negative Sentiment: Cybersecurity and insider-selling concerns remain: Amgen is investigating a material data breach involving patient and proprietary information. Separately, reported insider activity included four sales and no purchases over the past six months, which may weigh modestly on sentiment. Amgen reveals material cyber breach
Institutional Investors Weigh In On Amgen
Several institutional investors and hedge funds have recently bought and sold shares of AMGN. Sfam LLC bought a new stake in Amgen during the fourth quarter worth $38,000. Advocate Investing Services LLC acquired a new position in shares of Amgen during the 4th quarter worth $39,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Amgen during the 4th quarter worth $52,000. Binnacle Investments Inc lifted its position in shares of Amgen by 26.1% during the 3rd quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock worth $59,000 after buying an additional 43 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its stake in Amgen by 21.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 189 shares of the medical research company’s stock valued at $62,000 after buying an additional 33 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
